Pharmacodynamic and pharmacogenomic study of the nanoparticle conjugate of camptothecin CRLX101 for the treatment of cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 7, 2014, Pages 1477-1486

  Gaur, Shikha ^a   Wang, Yafan ^a   Kretzner, Leo ^a   Chen, Linling ^a   Yen, Terence ^a   Wu, Xiwei ^c   Yuan, Yate Ching ^c   Davis, Mark ^a   Yen, Yun ^a,b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b California Institute of Technology   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Camptothecin; HIF 1 ; Immunohistochemistry; Nanoparticle; Polymer conjugate; Solid tumor; Topoisomerase 1

Indexed keywords

CONTROLLED DRUG DELIVERY; DISEASES; GENES; NANOPARTICLES; PROTEINS; TARGETED DRUG DELIVERY; TOXICITY;

CAMPTOTHECIN (CPT); IMMUNOHISTOCHEMISTRY; POLYMER CONJUGATE; SOLID TUMORS; TOPOISOMERASES;

TUMORS;

CAMPTOTHECIN; CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; CRLX 101; CYCLODEXTRIN; DNA TOPOISOMERASE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; KI 67 ANTIGEN; NANOCONJUGATE; NANOPARTICLE; POLYMER; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CYTOKINE; IT-101; PRIMER DNA;

ADULT; ADVANCED CANCER; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG METABOLISM; FATIGUE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INOPERABLE CANCER; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NANOPHARMACEUTICS; NANOTOXICOLOGY; NEUTROPENIA; PANCREAS CANCER; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SURVIVAL TIME; THROMBOCYTOPENIA; TRIPLE NEGATIVE BREAST CANCER; TUMOR BIOPSY; BLOOD; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CAMPTOTHECIN; CELL PROLIFERATION; CYCLODEXTRINS; CYTOKINES; DNA PRIMERS; HUMANS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84912151114     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.04.003     Document Type: Article

References (49)

1. Dranitsaris G., Truter I., Lubbe M.S., Amir E., Evans W. Advances in cancer therapeutics and patient access to new drugs. Pharmacoeconomics 2011, 29(3):213-224.
2. Hertzberg R.P., Caranfa M.J., Hecht S.M. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry 1989, 28(11):4629-4638.
3. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., Kaufmann S.H. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993, 85(4):271-291.
4. Kehrer D.F., Soepenberg O., Loos W.J., Verweij J., Sparreboom A. Modulation of camptothecin analogs in the treatment of cancer: a review. Anticancer Drugs 2001, 12(2):89-105.
5. Husain I., Mohler J.L., Seigler H.F., Besterman J.M. Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 1994, 54(2):539-546.
6. Houghton P.J., Cheshire P.J., Hallman J.D., Lutz L., Friedman H.S., Danks M.K., et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995, 36(5):393-403.
7. Cheng J., Khin K.T., Jensen G.S., Liu A., Davis M.E. Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. Bioconjug Chem 2003, 14(5):1007-1017.
8. Cheng J., Khin K.T., Davis M.E. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm 2004, 1(3):183-193.
9. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46(12 Pt. 1):6387-6392.
10. Davis M.E. Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev 2009, 61(13):1189-1192.
11. Gaur S., Chen L., Yen T., Wang Y., Zhou B., Davis M., et al. Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine 2012, 8(5):721-730.
12. Schluep T., Cheng J., Khin K.T., Davis M.E. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol 2006, 57(5):654-662.
13. Schluep T., Hwang J., Hildebrandt I.J., Czernin J., Choi C.H., Alabi C.A., et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U S A 2009, 106(27):11394-11399.
14. Svenson S., Wolfgang M., Hwang J., Ryan J., Eliasof S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101. J Control Release 2011, 153(1):49-55.
15. Eliasof S., Lazarus D., Peters C.G., Case R.I., Cole R.O., Hwang J., et al. Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle. Proc Natl Acad Sci U S A 2013, 110(37):15127-15132.
16. Weiss G.J., Chao J., Neidhart J.D., Ramanathan R.K., Bassett D., Neidhart J.A., et al. First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. Invest New Drugs 2013, 31(4):986-1000.
17. Stoeltzing O., McCarty M.F., Wey J.S., Fan F., Liu W., Belcheva A., et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J Natl Cancer Inst 2004, 96(12):946-956.
18. Kato Y., Yashiro M., Noda S., Kashiwagi S., Matsuoka J., Fuyuhiro Y., et al. Expression of a hypoxia-associated protein, carbonic anhydrase-9, correlates with malignant phenotypes of gastric carcinoma. Digestion 2010, 82(4):246-251.
19. Wykoff C.C., Beasley N.J., Watson P.H., Turner K.J., Pastorek J., Sibtain A., et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60(24):7075-7083.
20. Litvak D.A., Papaconstantinou H.T., Evers B.M., Townsend C.M. Targeting molecular pathways with camptothecin as novel therapy for gastric cancer. J Gastrointest Surg 1999, 3(6):618-624.
21. Inoue K., Ozeki Y., Suganuma T., Sugiura Y., Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997, 79(2):206-213.
22. Maeda K., Chung Y.S., Ogawa Y., Takatsuka S., Kang S.M., Ogawa M., et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77(5):858-863.
23. Burmester J.K., Sedova M., Shapero M.H., Mansfield E. DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 2010, 632:99-124.
24. Bower J.E., Ganz P.A., Tao M.L., Hu W., Belin T.R., Sepah S., et al. Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 2009, 15(17):5534-5540.
25. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 2001, 933:222-234.
26. Eisenberger N.I., Inagaki T.K., Mashal N.M., Irwin M.R. Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 2010, 24(4):558-563.
27. Wang X., Xu S., Lu G., Feng J., Zhou X., Zhu C. Clinical significance of examining IL-2R in peripheral blood lymphocytes of patients with gastric cancer. Chin Med J (Engl) 2001, 114(12):1320-1322.
28. Chen Y., Shi M., Yu G.Z., Qin X.R., Jin G., Chen P., et al. Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 2012, 18(10):1123-1129.
29. Seruga B., Zhang H., Bernstein L.J., Tannock I.F. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008, 8(11):887-899.
30. Trompet S., de Craen A.J., Mooijaart S., Stott D.J., Ford I., Sattar N., et al. High Innate Production Capacity of Proinflammatory Cytokines Increases Risk for Death from Cancer: Results of the PROSPER Study. Clin Cancer Res 2009, 15(24):7744-7748.
31. Plones T., Krohn A., Burger M., Veelken H., Passlick B., Muller-Quernheim J., et al. Serum level of CC-chemokine ligand 18 is increased in patients with non-small-cell lung cancer and correlates with survival time in adenocarcinomas. PLoS ONE 2012, 7(7):e41746.
32. Portenoy R.K., Itri L.M. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999, 4(1):1-10.
33. Morris R., Munkarah A. Alternate dosing schedules for topotecan in the treatment of recurrent ovarian cancer. Oncologist 2002, 7(Suppl. 5):29-35.
34. Numbenjapon T., Wang J., Colcher D., Schluep T., Davis M.E., Duringer J., et al. Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models. Clin Cancer Res 2009, 15(13):4365-4373.
35. Gilbert D.C., Chalmers A.J., El-Khamisy S.F. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2012, 106(1):18-24.
36. Ikeguchi M., Arai Y., Maeta Y., Ashida K., Katano K., Wakatsuki T. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today 2011, 41(9):1196-1199.
37. Horisberger K., Erben P., Muessle B., Woernle C., Stroebel P., Kaehler G., et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009, 20(6):519-524.
38. Koopman M., Antonini N.F., Douma J., Wals J., Honkoop A.H., Erdkamp F.L., et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007, 370(9582):135-142.
39. Koopman M., Venderbosch S., van Tinteren H., Ligtenberg M.J., Nagtegaal I., Van Krieken J.H., et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009, 45(11):1999-2006.
40. Tan P.H., Bay B.H., Yip G., Selvarajan S., Tan P., Wu J., et al. Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 2005, 18(3):374-381.
41. Krishnamachary B., Glunde K., Wildes F., Mori N., Takagi T., Raman V., et al. Noninvasive detection of lentiviral-mediated choline kinase targeting in a human breast cancer xenograft. Cancer Res 2009, 69(8):3464-3471.
42. Rapisarda A., Uranchimeg B., Sordet O., Pommier Y., Shoemaker R.H., Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Res 2004, 64(4):1475-1482.
43. Rapisarda A., Zalek J., Hollingshead M., Braunschweig T., Uranchimeg B., Bonomi C.A., et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004, 64(19):6845-6848.
44. Fondevila C., Metges J.P., Fuster J., Grau J.J., Palacin A., Castells A., et al. p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer 2004, 90(1):206-215.
45. Creaven P.J., Allen L.M., Muggia F.M. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 1972, 56(5):573-578.
46. Ikegami T., Ha L., Arimori K., Latham P., Kobayashi K., Ceryak S., et al. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea. Cancer Res 2002, 62(1):179-187.
47. Nakashima E., Oya A., Kubota Y., Kanada N., Matsushita R., Takeda K., et al. A candidate for cancer gene therapy: MIP-1 alpha gene transfer to an adenocarcinoma cell line reduced tumorigenicity and induced protective immunity in immunocompetent mice. Pharm Res 1996, 13(12):1896-1901.
48. Dehqanzada Z.A., Storrer C.E., Hueman M.T., Foley R.J., Harris K.A., Jama Y.H., et al. Correlations between serum monocyte chemotactic protein-1 levels, clinical prognostic factors, and HER-2/neu vaccine-related immunity in breast cancer patients. Clin Cancer Res 2006, 12(2):478-486.
49. Rosen P.J., Sweeney C.J., Park D.J., Beaupre D.M., Deng H., Leitch I.M., et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin Cancer Res 2010, 16(9):2677-2687.